EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens

Nityanand Srivastava, Salman Sadullah Usmani, Rajasekaran Subbarayan, Rashmi Saini, Pranav Kumar Pandey

Frontiers in Oncology · 10.07.2023 · 13

DOI: 10.3389/fonc.2023.1199105 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 10.07.2023. Verfasst von Nityanand Srivastava und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, United States. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 347 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is one of the deadliest subtypes of breast cancer (BC) for its high aggressiveness, heterogeneity, and hypoxic nature. Based on biological and clinical observations the TNBC related mortality is very high worldwide. Emerging studies have clearly demonstrated that hypoxia regulates the critical metabolic, developmental, and survival pathways in TNBC, which include glycolysis and angiogenesis. Alterations to these pathways accelerate the cancer stem cells (CSCs) enrichment and immune escape, which further lead to tumor invasion, migration, and metastasis. Beside this, hypoxia also manipulates the epigenetic plasticity and DNA damage response (DDR) to syndicate TNBC survival and its progression. Hypoxia fundamentally creates the low oxygen condition responsible for the alteration in Hypoxia-Inducible Factor-1alpha (HIF-1α) signaling within the tumor microenvironment, allowing tumors to survive and making them resistant to various therapies. Therefore, there is an urgent need for society to establish target-based therapies that overcome the resistance and limitations of the current treatment plan for TNBC. In this review article, we have thoroughly discussed the plausible significance of HIF-1α as a target in various therapeutic regimens such as chemotherapy, radiotherapy, immunotherapy, anti-angiogenic therapy, adjuvant therapy photodynamic therapy, adoptive cell therapy, combination therapies, antibody drug conjugates and cancer vaccines. Further, we also reviewed here the intrinsic mechanism and existing issues in targeting HIF-1α while improvising the current therapeutic strategies. This review highlights and discusses the future perspectives and the major alternatives to overcome TNBC resistance by targeting hypoxia-induced signaling.

Schlagwörter

Stichwörter der Autor:innen

DNA damage responseHIF-1HypoxiaTNBCcancer vaccineschemotherapyimmune escapeimmunotherapy

Autor:innen und Institutionen

  • Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, United States.
  • Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, United States.
  • Department of Radiation Oncology, Albert Einstein College of Medicine, Bronx, NY, United States.
  • Research, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Educations, Chennai, India.
  • Department of Zoology, Gargi College, University of Delhi, New Delhi, India.
  • Dr. R.P. Centre for Opthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.

Zitieren

APA

Srivastava, N., Usmani, S. S., Subbarayan, R., Saini, R., & Pandey, P. K. (2023). Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1199105

Vancouver

Srivastava N, Usmani SS, Subbarayan R, Saini R, Pandey PK. Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1199105

BibTeX
@article{Srivastava2023,
  author = {Srivastava, Nityanand and Usmani, Salman Sadullah and Subbarayan, Rajasekaran and Saini, Rashmi and Pandey, Pranav Kumar},
  title = {Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens},
  journal = {Frontiers in Oncology},
  year = {2023},
  volume = {13},
  doi = {10.3389/fonc.2023.1199105}
}
Kostenlos starten →